Contents

Search

statin deprescribing

Indications: - limited prognosis, palliative care [1] Contraindications: - in elderly patients receiving statin, antihypertensive(s), hypoglycemic(s) & antiplatelet agent(s) (mean age 76 years, cardiovascular disease implied by medications), deprescribing statin while maintaining other medications is associated with increased risk for adverse cardiovascular outcome(s) (RR=1.14) [2]* - among elderly >= 75 years with >= 5 years of statin therapy, discontinuation of statin associated with higher risk of major cardiovascular event [3] - relative risk; 1.32 (primary prevention); 1.28 (secondary prevention) [3] * senior author with conflict of interest disclosures [2]

Related

HMG CoA reductase inhibitor (statin)

General

medication deprescribing

References

  1. Kutner JS et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: A randomized clinical trial. JAMA Intern Med 2015 May; 175:691 PMID: 25798575
  2. Rea F, Biffi A, Ronco R et al Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy. JAMA Netw Open. 2021;4(6):e2113186 PMID: 34125221
  3. Thompson W, Morin L, Jarbol DE et al Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA Netw Open. 2021 Dec 1;4(12):e2136802. PMID: 34854906 PMCID: PMC8640890 Free PMC article.